G. M. Bartelds

2.5k total citations · 2 hit papers
15 papers, 1.9k citations indexed

About

G. M. Bartelds is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Genetics. According to data from OpenAlex, G. M. Bartelds has authored 15 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Genetics. Recurrent topics in G. M. Bartelds's work include Systemic Lupus Erythematosus Research (10 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). G. M. Bartelds is often cited by papers focused on Systemic Lupus Erythematosus Research (10 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). G. M. Bartelds collaborates with scholars based in Netherlands, United States and United Kingdom. G. M. Bartelds's co-authors include Gertjan Wolbink, Michael T. Nurmohamed, Carla A. Wijbrandts, Steven O. Stapel, Ben A. C. Dijkmans, Willem F. Lems, LA Aarden, P. P. Tak, Paul P. Tak and Pauline A. van Schouwenburg and has published in prestigious journals such as JAMA, Annals of the Rheumatic Diseases and Journal of Immunological Methods.

In The Last Decade

G. M. Bartelds

15 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

2011 597 citations G. M. Bartelds JAMA profile →
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

2007 448 citations G. M. Bartelds, Carla A. Wijbrandts et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. M. Bartelds Netherlands	13	1.0k	978	714	334	323	15	1.9k
William Shergy United States	19	561 0.6×	1.2k 1.3×	274 0.4×	481 1.4×	300 0.9×	24	1.9k
Artur Racewicz Poland	9	660 0.7×	933 1.0×	325 0.5×	304 0.9×	344 1.1×	14	1.5k
Dana Tegzová Czechia	15	1.0k 1.0×	1.7k 1.7×	657 0.9×	341 1.0×	235 0.7×	22	2.1k
C. Krieckaert Netherlands	16	578 0.6×	702 0.7×	328 0.5×	212 0.6×	166 0.5×	44	1.1k
E. Hessey United Kingdom	6	732 0.7×	1.7k 1.7×	615 0.9×	650 1.9×	710 2.2×	8	2.4k
Piotr Leszczyński Poland	20	813 0.8×	914 0.9×	295 0.4×	269 0.8×	108 0.3×	70	1.5k
Leonor Barile-Fabris Mexico	13	415 0.4×	815 0.8×	206 0.3×	145 0.4×	111 0.3×	30	1.2k
G. R. Burmester Germany	14	464 0.5×	834 0.9×	297 0.4×	285 0.9×	134 0.4×	43	1.4k
Michelle Petri United States	17	1.2k 1.2×	1.4k 1.5×	258 0.4×	228 0.7×	42 0.1×	18	2.1k
Harry R. Koene Netherlands	14	652 0.6×	128 0.1×	657 0.9×	253 0.8×	241 0.7×	36	1.3k

Countries citing papers authored by G. M. Bartelds

Since Specialization

Citations

This map shows the geographic impact of G. M. Bartelds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. M. Bartelds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. M. Bartelds more than expected).

Fields of papers citing papers by G. M. Bartelds

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. M. Bartelds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. M. Bartelds. The network helps show where G. M. Bartelds may publish in the future.

Co-authorship network of co-authors of G. M. Bartelds

This figure shows the co-authorship network connecting the top 25 collaborators of G. M. Bartelds. A scholar is included among the top collaborators of G. M. Bartelds based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. M. Bartelds. G. M. Bartelds is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Bartelds, G. M., C. Krieckaert, Franktien Turkstra, et al.. (2011). Venous and arterial thromboembolic events in adalimumab‐treated patients with antiadalimumab antibodies: A case series and cohort study. Arthritis & Rheumatism. 63(4). 877–883. 91 indexed citations

Bartelds, G. M.. (2011). Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up. JAMA. 305(14). 1460–1460. 597 indexed citations breakdown →

Visman, I.M., G. M. Bartelds, Wouter Ouwerkerk, et al.. (2011). Effect of the Application of Trial Inclusion Criteria on the Efficacy of Adalimumab Therapy in a Rheumatoid Arthritis Cohort. The Journal of Rheumatology. 38(9). 1884–1890. 1 indexed citations

Krieckaert, C., G. M. Bartelds, & Gertjan Wolbink. (2010). Immunogenicity of biologic therapies—we need tolerance. Nature Reviews Rheumatology. 6(10). 558–559. 10 indexed citations

Bartelds, G. M., Els de Groot, Michael T. Nurmohamed, et al.. (2010). Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Research & Therapy. 12(6). R221–R221. 56 indexed citations

Bartelds, G. M., et al.. (2010). The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Research & Therapy. 12(5). 217–217. 86 indexed citations

Jamnitski, Anna, G. M. Bartelds, Michael T. Nurmohamed, et al.. (2010). The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Annals of the Rheumatic Diseases. 70(2). 284–288. 147 indexed citations

Schouwenburg, Pauline A. van, G. M. Bartelds, M. Hart, et al.. (2010). A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. Journal of Immunological Methods. 362(1-2). 82–88. 131 indexed citations

Bartelds, G. M., Carla A. Wijbrandts, Michael T. Nurmohamed, et al.. (2009). Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Annals of the Rheumatic Diseases. 69(5). 817–821. 174 indexed citations

10.

Bartelds, G. M., Carla A. Wijbrandts, Michael T. Nurmohamed, et al.. (2009). Anti‐adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin‐10 gene polymorphisms. Arthritis & Rheumatism. 60(8). 2541–2542. 62 indexed citations

11.

Hoving, Jan L., G. M. Bartelds, J. K. Sluiter, et al.. (2009). Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6‐month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scandinavian Journal of Rheumatology. 38(4). 246–250. 38 indexed citations

12.

Bos, Wouter H, Jennie Ursum, Niek de Vries, et al.. (2008). The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels. Annals of the Rheumatic Diseases. 67(9). 1347–1350. 22 indexed citations

13.

Bos, Wouter H, G. M. Bartelds, Marijn Vis, et al.. (2008). Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 68(4). 558–563. 24 indexed citations

14.

Bos, Wouter H, G. M. Bartelds, Gertjan Wolbink, et al.. (2008). Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.. PubMed. 35(10). 1972–7. 47 indexed citations

15.

Bartelds, G. M., Carla A. Wijbrandts, Michael T. Nurmohamed, et al.. (2007). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases. 66(7). 921–926. 448 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact